scholarly journals Biodegradable polymeric micelles coencapsulating paclitaxel and honokiol: a strategy for breast cancer therapy in vitro and in vivo

2017 ◽  
Vol Volume 12 ◽  
pp. 1499-1514 ◽  
Author(s):  
Ning Wang ◽  
Zhihan Wang ◽  
Shihong Nie ◽  
Linjiang Song ◽  
Tao He ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Polymeric Micelles ◽  
Breast Cancer Therapy

scholarly journals Hydrogel-Mediated DOX⋅HCl/PTX Delivery System for Breast Cancer Therapy

2019 ◽  
Vol 20 (19) ◽  
pp. 4671
Author(s):  
Hoon Hyun ◽  
Young Yoo ◽  
So Kim ◽  
Hyun Ko ◽  
Heung Chun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Anticancer Effect ◽  
Breast Cancer Therapy ◽  
Glycol Chitosan ◽  
Burst Period ◽  
Delivery Approach ◽  
Dual Drug

We used a hydrogel-mediated dual drug delivery approach, based on an injectable glycol chitosan (GC) hydrogel, doxorubicin hydrochloride (DOX⋅HCl), and a complex of beta-cyclodextrin (β-CD) and paclitaxel (PTX) (GDCP) for breast cancer therapy in vitro and in vivo. The hydrogel was swollen over 3 days and remained so thereafter. After an initial burst period of 7 hours, the two drugs were released in a sustained manner for 7 days. The in vitro cell viability test showed that GDCP had a better anticancer effect than well plate and DOX⋅HCl/PTX (DP). In addition, the in vivo tests, which evaluated the anticancer effect, systemic toxicity, and histology, proved the feasibility of GDCP as a clinical therapy for breast cancer.

Novel folate-targeted docetaxel-loaded nanoparticles for tumour targeting: in vitro and in vivo evaluation

RSC Advances ◽  
2016 ◽  
Vol 6 (69) ◽  
pp. 64306-64314 ◽  
Author(s):  
M. H. Han ◽  
Z. T. Li ◽  
D. D. Bi ◽  
Y. F. Guo ◽  
H. X. Kuang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Folic Acid ◽  
Cancer Therapy ◽  
Targeted Delivery ◽  
Tumour Targeting ◽  
Breast Cancer Therapy ◽  
In Vivo Evaluation ◽  
Targeted Delivery System

Cholesterol-PEG1000-FA (folic acid) was synthesized as a stabilizer to encapsulate DTX, for the construction of a promising targeted delivery system for breast cancer therapy.

Folic acid modified copper oxide nanoparticles for targeted delivery in in vitro and in vivo systems

RSC Advances ◽  
2015 ◽  
Vol 5 (83) ◽  
pp. 68169-68178 ◽  
Author(s):  
Dipranjan Laha ◽  
Arindam Pramanik ◽  
Sourav Chattopadhyay ◽  
Sandip kumar Dash ◽  
Somenath Roy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Folic Acid ◽  
Cancer Therapy ◽  
Copper Oxide ◽  
Targeted Delivery ◽  
Copper Oxide Nanoparticles ◽  
Oxide Nanoparticles ◽  
Breast Cancer Therapy

Targeted delivery of copper oxide nanoparticles for breast cancer therapy.

Stimuli-responsive Drug Delivery Nanocarriers in the Treatment of Breast Cancer

2020 ◽  
Vol 27 (15) ◽  
pp. 2494-2513 ◽  
Author(s):  
João A. Oshiro-Júnior ◽  
Camila Rodero ◽  
Gilmar Hanck-Silva ◽  
Mariana R. Sato ◽  
Renata Carolina Alves ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Drug Delivery ◽  
Cancer Therapy ◽  
Near Infrared ◽  
Stimuli Responsive ◽  
Breast Cancer Therapy ◽  
Physical Stimuli ◽  
Pharmaceutical Properties

Stimuli-responsive drug-delivery nanocarriers (DDNs) have been increasingly reported in the literature as an alternative for breast cancer therapy. Stimuli-responsive DDNs are developed with materials that present a drastic change in response to intrinsic/chemical stimuli (pH, redox and enzyme) and extrinsic/physical stimuli (ultrasound, Near-infrared (NIR) light, magnetic field and electric current). In addition, they can be developed using different strategies, such as functionalization with signaling molecules, leading to several advantages, such as (a) improved pharmaceutical properties of liposoluble drugs, (b) selectivity with the tumor tissue decreasing systemic toxic effects, (c) controlled release upon different stimuli, which are all fundamental to improving the therapeutic effectiveness of breast cancer treatment. Therefore, this review summarizes the use of stimuli-responsive DDNs in the treatment of breast cancer. We have divided the discussions into intrinsic and extrinsic stimuli and have separately detailed them regarding their definitions and applications. Finally, we aim to address the ability of these stimuli-responsive DDNs to control the drug release in vitro and the influence on breast cancer therapy, evaluated in vivo in breast cancer models.

A pH-responsive natural cyclopeptide RA-V drug formulation for improved breast cancer therapy

2015 ◽  
Vol 3 (22) ◽  
pp. 4514-4523 ◽  
Author(s):  
Zeng-Ying Qiao ◽  
Di Zhang ◽  
Chun-Yuan Hou ◽  
Si-Meng Zhao ◽  
Ya Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Tumor Therapy ◽  
Ph Sensitive ◽  
Drug Formulation ◽  
Ph Responsive ◽  
Breast Cancer Therapy

The co-encapsulation of RA-V cyclopeptide and SQ molecules in pH-sensitive PAE micelles for efficient tumor therapy and imaging in vitro and in vivo.

Efficient in vitro and in vivo docetaxel delivery mediated by pH-sensitive LPHNPs for effective breast cancer therapy

2021 ◽  
Vol 203 ◽  
pp. 111760
Author(s):  
Rajesh Singh Jadon ◽  
Gajanand Sharma ◽  
Neeraj K. Garg ◽  
Nikunj Tandel ◽  
Kavita R. Gajbhiye ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Ph Sensitive ◽  
Breast Cancer Therapy

scholarly journals A GSH/CB Dual-Controlled Self-Assembled Nanomedicine for High-Efficacy Doxorubicin-Resistant Breast Cancer Therapy

2022 ◽  
Vol 12 ◽  
Author(s):  
Yang Yang ◽  
Quanfeng Zhao ◽  
Zhe Peng ◽  
Yunjiang Zhou ◽  
Miao-Miao Niu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Adverse Reactions ◽  
Caspase 3 ◽  
Anticancer Agent ◽  
High Efficacy ◽  
Breast Cancer Therapy ◽  
Mcf 7

Chemoresistance is a major therapeutic obstacle in the treatment of breast cancer. Therefore, how to overcome chemoresistance is a problem to be solved. Here, a glutathione (GSH)/cathepsin B (CB) dual-controlled nanomedicine formed by cyclic disulfide-bridged peptide (cyclic-1a) as a potent anticancer agent is reported. Under the sequential treatment of GSH and CB, cyclic-1a can efficiently self-assemble into nanofibers. In vitro studies show that cyclic-1a promotes the apoptosis of MCF-7/DOX cells by inducing the cleavages of caspase-3 and PARP. In vivo studies confirm that cyclic-1a significantly inhibits the progression of MCF-7/DOX cells-derived xenograft in nude mice, with no obvious adverse reactions. This study provides a paradigm of GSH/CB dual-controlled nanomedicine for high-efficacy and low-toxic DOX-resistant breast cancer therapy.

Sign in / Sign up

Export Citation Format

Share Document